Anti-angiogenic active immunotherapy: a new approach to cancer treatment

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Tumor angiogenesis is crucial for tumor growth, progression, and metastasis.
• Key regulators of angiogenesis include vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and epidermal growth factor (EGF).
• Anti-angiogenic therapies represent a significant area of cancer treatment research.

Purpose of the Study:

• To review anti-angiogenic active immunotherapies for cancer treatment.
• To discuss vaccination strategies utilizing xenogeneic and non-xenogeneic homologous molecules.
• To highlight advancements in harnessing the immune system to combat tumor angiogenesis.

Main Methods:

• Literature review of anti-angiogenic immunotherapies.
• Analysis of vaccination approaches using homologous molecules (xenogeneic and non-xenogeneic).
• Discussion of the mechanisms underlying these immunotherapies.

Main Results:

• Vaccination with homologous molecules can induce an immune response against tumor angiogenesis.
• Both xenogeneic and non-xenogeneic approaches show potential in preclinical and clinical settings.
• These strategies aim to disrupt tumor blood supply, thereby inhibiting tumor growth.

Conclusions:

• Anti-angiogenic active immunotherapy is a promising strategy for cancer treatment.
• Vaccination-based approaches offer a novel way to target tumor angiogenesis.
• Further research is needed to optimize these immunotherapies for clinical application.